Site professionnel spécialisé en Rhumatologie
POS0073. Lindström U, Di Giuseppe D, Exarchou S et al. Comparison of time from methotrexate initiation to start of a b/tsDMARD in psoriatic arthritis versus rheumatoid arthritis. A nationwide register-based…
OP0135. Meissner Y, Albrecht K, Kekow J et al. Risk of cardiovascular events under janus kinase inhibitors in patients with rheumatoid arthritis: observational data from the German RABBIT register. Eular…
OP0138. Sánchez-Alonso F, Bohórquez C, Diaz-Torne C et al. Risk of cancer after biologic and targeted synthetic DMARDs initiation in patients with rheumatic diseases and a history of prior malignancy:…
OP0016. Deodhar A, Van den Bosch F, Poddubnyy D et al. Efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis: a double-blind, randomized, placebo-controlled phase 3 trial.…
OP0255. Merola JF, McInnes I, Ritchlin CT et al. Bimekizumab in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: 16-week efficacy & safety from…
OP0221. Ruperto N, Chertok E, Dehoorne J et al. Efficacy of secukinumab in enthesitis-related arthritis: results from a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 study (JUNIPERA). Eular 2022. Figure…
OP0263. Hartman L, Opris-Belinski D, Bos R et al. Favorable balance of benefit and harm of long-term, low-dose prednisolone added to standard treatment in rheumatoid arthritis patients aged 65+: the…
OP0153. Hamroun S, Couderc M, Flipo RM et al. Preconceptional nsaid treatment is associated with longer time-to-conception in women with spondyloarthritis: analysis of the prospective GR2 cohort. Eular 2022. OP0126.…
OP0270. Boers M, Hartman L, Opris-Belinski D et al. Tapering of long-term, low-dose glucocorticoids in senior rheumatoid arthritis patients: follow-up of the pragmatic, multicentre, placebo-controlled GLORIA trial. Eular 2022.
OP0023. Deodhar A, Kivitz A, Magrey M et al. A randomized, double-blind trial comparing secukinumab 300 mg and 150 mg at week 52 in patients with ankylosing spondylitis who did…
OP0261. Michielsens C, den Broeder N, van den Hoogen F et al. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomized controlled…
OP0070. Krijbolder D, Verstappen M, van Dijk B et al. Intervention with methotrexate in arthralgia at risk for rheumatoid arthritis to reduce the development of persistent arthritis and its disease…
Abstract OP0020. Hellamand P, Van de Sande MGH, Midtbøll Ørnbjerg L et al. Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries…
OP0269. Szekanecz C, Charles-Schoeman C, Vranix I et al. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. Eular 2022.
